vs

Side-by-side financial comparison of Dermata Therapeutics, Inc. (DRMA) and TREASURE GLOBAL INC (TGL). Click either name above to swap in a different company.

TREASURE GLOBAL INC is the larger business by last-quarter revenue ($182.5K vs $92.8K, roughly 2.0× Dermata Therapeutics, Inc.). TREASURE GLOBAL INC runs the higher net margin — -1169.1% vs -1853.3%, a 684.2% gap on every dollar of revenue. On growth, Dermata Therapeutics, Inc. posted the faster year-over-year revenue change (531.8% vs -12.0%).

Dermata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm developing novel targeted therapies for dermatological diseases including acne, psoriasis and inflammatory skin disorders. It serves U.S. patients and healthcare providers, advancing pipeline candidates through trials to address unmet dermatological care needs.

Treasure Global Inc is a consumer technology company offering integrated digital commerce solutions, customer loyalty rewards programs, and cashless payment services. It primarily operates across Southeast Asian markets, serving individual users and small-to-medium enterprise clients.

DRMA vs TGL — Head-to-Head

Bigger by revenue
TGL
TGL
2.0× larger
TGL
$182.5K
$92.8K
DRMA
Growing faster (revenue YoY)
DRMA
DRMA
+543.7% gap
DRMA
531.8%
-12.0%
TGL
Higher net margin
TGL
TGL
684.2% more per $
TGL
-1169.1%
-1853.3%
DRMA

Income Statement — Q3 FY2023 vs Q1 FY2026

Metric
DRMA
DRMA
TGL
TGL
Revenue
$92.8K
$182.5K
Net Profit
$-1.7M
$-2.1M
Gross Margin
0.7%
Operating Margin
-1953.3%
-953.5%
Net Margin
-1853.3%
-1169.1%
Revenue YoY
531.8%
-12.0%
Net Profit YoY
29.1%
-124.5%
EPS (diluted)
$-0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DRMA
DRMA
TGL
TGL
Q3 25
$182.5K
Q2 25
$1.2M
Q1 25
$666.5K
Q4 24
$301.9K
Q3 24
$207.4K
Q2 24
$293.0K
Q1 24
$1.6M
Q4 23
$6.7M
Net Profit
DRMA
DRMA
TGL
TGL
Q3 25
$-2.1M
Q2 25
Q1 25
$1.3M
Q4 24
$-232.3K
Q3 24
$-950.7K
Q2 24
Q1 24
$-1.7M
Q4 23
$-1.2M
Gross Margin
DRMA
DRMA
TGL
TGL
Q3 25
0.7%
Q2 25
68.2%
Q1 25
73.0%
Q4 24
74.2%
Q3 24
83.0%
Q2 24
31.0%
Q1 24
13.6%
Q4 23
5.1%
Operating Margin
DRMA
DRMA
TGL
TGL
Q3 25
-953.5%
Q2 25
Q1 25
-6.5%
Q4 24
-229.5%
Q3 24
-391.4%
Q2 24
Q1 24
-85.9%
Q4 23
-16.2%
Net Margin
DRMA
DRMA
TGL
TGL
Q3 25
-1169.1%
Q2 25
Q1 25
189.0%
Q4 24
-77.0%
Q3 24
-458.5%
Q2 24
Q1 24
-107.3%
Q4 23
-17.9%
EPS (diluted)
DRMA
DRMA
TGL
TGL
Q3 25
$-0.38
Q2 25
Q1 25
$1.09
Q4 24
$-11.32
Q3 24
$-17.62
Q2 24
Q1 24
$-116.03
Q4 23
$-2.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DRMA
DRMA
TGL
TGL
Cash + ST InvestmentsLiquidity on hand
$6.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$6.4M
$12.0M
Total Assets
$7.3M
$16.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DRMA
DRMA
TGL
TGL
Q3 25
Q2 25
Q1 25
$2.5K
Q4 24
$504.3K
Q3 24
$44.1K
Q2 24
$171.6K
Q1 24
Q4 23
Stockholders' Equity
DRMA
DRMA
TGL
TGL
Q3 25
$12.0M
Q2 25
$10.7M
Q1 25
$29.1M
Q4 24
$18.4M
Q3 24
$6.3M
Q2 24
$3.4M
Q1 24
$3.1M
Q4 23
$3.7M
Total Assets
DRMA
DRMA
TGL
TGL
Q3 25
$16.6M
Q2 25
$14.9M
Q1 25
$30.4M
Q4 24
$19.1M
Q3 24
$7.1M
Q2 24
$4.3M
Q1 24
$4.2M
Q4 23
$4.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DRMA
DRMA
TGL
TGL
Operating Cash FlowLast quarter
$-1.8M
Free Cash FlowOCF − Capex
$-2.4M
FCF MarginFCF / Revenue
-1318.2%
Capex IntensityCapex / Revenue
353.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DRMA
DRMA
TGL
TGL
Q3 25
$-1.8M
Q2 25
$-9.5M
Q1 25
$-4.2M
Q4 24
$-606.2K
Q3 24
$-976.3K
Q2 24
$-4.7M
Q1 24
$-1.1M
Q4 23
$-1.2M
Free Cash Flow
DRMA
DRMA
TGL
TGL
Q3 25
$-2.4M
Q2 25
$-9.5M
Q1 25
$-4.2M
Q4 24
Q3 24
Q2 24
$-4.7M
Q1 24
$-1.1M
Q4 23
$-1.2M
FCF Margin
DRMA
DRMA
TGL
TGL
Q3 25
-1318.2%
Q2 25
-822.4%
Q1 25
-635.6%
Q4 24
Q3 24
Q2 24
-1614.2%
Q1 24
-67.1%
Q4 23
-17.9%
Capex Intensity
DRMA
DRMA
TGL
TGL
Q3 25
353.3%
Q2 25
1.3%
Q1 25
0.3%
Q4 24
Q3 24
Q2 24
5.7%
Q1 24
0.0%
Q4 23
0.1%
Cash Conversion
DRMA
DRMA
TGL
TGL
Q3 25
Q2 25
Q1 25
-3.36×
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons